Bromodomain and extraterminal domain inhibitors (BETi) represent promising therapeutic agents for metastatic melanoma, yet their mechanism of action remains unclear. Here we interrogated the transcriptional effects of BETi and identified AMIGO2, a transmembrane molecule, as a BET target gene essential for melanoma cell survival. AMIGO2 is upregulated in melanoma cells and tissues compared to human melanocytes and nevi, and AMIGO2 silencing in melanoma cells induces G1/S arrest followed by apoptosis. We identified the pseudokinase PTK7 as an AMIGO2 interactor whose function is regulated by AMIGO2. Epigenomic profiling and genome editing revealed that AMIGO2 is regulated by a melanoma-specific BRD2/4-bound promoter and super-enhancer configuration. Upon BETi treatment, BETs are evicted from these regulatory elements, resulting in AMIGO2 silencing and changes in PTK7 proteolytic processing. Collectively, this study uncovers mechanisms underlying the therapeutic effects of BETi in melanoma and reveals the AMIGO2-PTK7 axis as a targetable pathway for metastatic melanoma.
In Brief
BET proteins play a central role in melanoma maintenance. By interrogating the effects of BET inhibition on melanoma transcriptional programs and regulatory elements, Fontanals-Cirera and Hasson et al. identified the transmembrane protein AMIGO2 as a survival factor whose expression is regulated by BETand FOSL/TEAD-bound DNA regulatory elements.
INTRODUCTION
Melanoma is the most aggressive form of skin cancer, with rising incidence (Whiteman et al., 2016) . Melanoma development and progression have been mainly attributed to genetically altered oncogenes (e.g., BRAF, NRAS) and tumor suppressors (e.g., CDKN2A, PTEN, NF1) (Hodis et al., 2012) , some of which have provided the basis for the development of effective targeted therapies (e.g., mutant-BRAF and MEK inhibitors) (Chapman et al., 2011; Kim et al., 2013) . Agents targeting the immune microenvironment (e.g., anti-CTLA-4 and anti-PD-1/PD-L1) have also shown efficient and durable responses (Postow et al., 2015) . Collectively, however, these therapies are administered to particular subsets of patients and relapse with treatment-refractory disease, and/or significant toxicities commonly occur Lito et al., 2013) . While these approaches have significantly improved outcome for some metastatic melanoma patients, their limitations underscore the need for new therapeutic strategies.
Deregulation of the epigenome has emerged as a critical step in the activation and maintenance of aberrant transcriptional programs in melanoma pathogenesis (Ceol et al., 2011; Kapoor et al., 2010; Lian et al., 2012; Souroullas et al., 2016; Vardabasso et al., 2015; Zingg et al., 2015) , which provides a basis for targeting chromatin regulators as a viable anti-cancer strategy. Particularly appealing are pharmacological compounds that displace factors involved in transcriptional regulation from chromatin, such as the BET proteins (Dawson et al., 2011; Filippakopoulos and Knapp, 2014; Gallagher et al., 2014; Mertz et al., 2011; Puissant et al., 2013; Segura et al., 2013) . The BET family consists of BRD2, BRD3, BRD4, and BRDT (testis-specific), which are ''readers'' of acetyl-lysine residues and recruit chromatin-modifying enzymes and transcriptional regulators to DNA regulatory elements. BRD4 is enriched at promoters, enhancers, and clusters of enhancers, termed super-enhancers (SEs), where it interacts with transcription factors (TFs) and components of the transcriptional machinery to promote expression of lineage-specific genes (Adam et al., 2015; Heinz et al., 2015; Whyte et al., 2013; Di Micco et al., 2014) , while BRD2 binds to promoters occupied by the histone variant H2A.Z (Draker et al., 2012; Surface et al., 2016; Vardabasso et al., 2015) and a subset of CTCF binding sites, where it maintains transcriptional boundaries (Hsu et al., 2017) .
Our groups and others reported that BRD2 and BRD4 are overexpressed in melanoma tissues and are essential for tumor maintenance (Gallagher et al., 2014; Segura et al., 2013; Vardabasso et al., 2015) . Silencing of BRD2 and BRD4, as well as BET inhibition, impairs melanoma growth, suggesting that BETs regulate pro-proliferative and/or survival genes (Gallagher et al., 2014; Segura et al., 2013; Vardabasso et al., 2015) . In turn, we hypothesized that examining the transcriptional programs of BET inhibition would (1) reveal novel melanoma-promoting genes that are not necessarily genetically altered, (2) expose molecular vulnerabilities that can be exploited therapeutically, and (3) provide a mechanistic understanding of BETi anti-tumoral effects that could further support their use for melanoma patients.
Here, we integrated the transcriptional signature of BET inhibition in melanoma with genes that are significantly upregulated relative to normal human melanocytes (NHM), in order to identify melanoma pro-tumorigenic factors. A loss-of-function screen of a subset of these genes and subsequent functional characterization uncovered AMIGO2, which encodes a type I transmembrane protein of the leucine-rich repeat (LRR) and Ig-like super family, as a melanoma survival gene. AMIGO2 is upregulated in melanoma tissues, and its silencing significantly impairs melanoma growth. Through a mass spectrometry study, we identified PTK7, a pseudo-tyrosine kinase, as an AMIGO2 interactor. We further demonstrated that AMIGO2 regulates PTK7 function and that PTK7 is also required for melanoma cell survival.
To address BET-mediated AMIGO2 transcription, we characterized the melanoma enhancer landscape. We found AMIGO2, as well as additional pro-tumorigenic genes, to be associated with SEs not present in NHMs. Upon BET inhibition, BRD2 and BRD4 are displaced from a subset of melanoma SEs and corresponding promoters, resulting in decreased expression of SEassociated genes. We identified enrichment of FOSL2 and TEAD4 TFs at melanoma SEs, including those of AMIGO2, which directly regulate its expression. Together, our data indicate that AMIGO2 is sensitive to BETi, displays increased expression in melanoma tissues, and acquires BET-regulated SEs in melanoma. Moreover, AMIGO2 is required for melanoma survival and interacts with pro-survival receptor PTK7. Our study further illustrates the value of leveraging the BETi-associated transcriptome as an effective strategy to identify pro-tumorigenic genes and therapeutic targets in melanoma.
RESULTS

Transcriptional Profiling of BETi-Treated Melanoma Cells Reveals Putative Pro-tumorigenic Genes
We utilized BETi to examine the BET-regulated transcriptome of malignant melanoma. These diazepine-based small molecules occupy the N-terminal tandem bromodomains of BETs and impair their binding to acetylated lysines (Filippakopoulos and Knapp, 2014) . Two BETi-sensitive melanoma cells of distinct genetic background (SKmel147, NRAS Q61R and 501MEL,
BRAF V600E
) were treated with JQ1 (JQ1 [+] ) and enantiomer (JQ1 [À] ) (Filippakopoulos et al., 2010) for 6 and 24 hr, followed by RNA sequencing (RNA-seq) (Figures 1A and S1A; Table S1 ). BETi led to significant transcriptional changes at 6 hr, which were sustained at 24 hr of treatment (Figures S1B and S1C) . By further examining genes downregulated in both melanoma cell lines at 6 hr, at 24 hr, or at both time points, we identified a core network of $800 JQ1-sensitive genes (Figures 1A and 1B;  Table S1 ). Gene ontology (GO) classification showed enrichment for gene functions such as regulation of cell cycle ( Figure S1D ), consistent with the proliferative arrest observed following BET inhibition (Segura et al., 2013; Vardabasso et al., 2015) .
Next, we determined the genes that are overexpressed in melanoma cells compared to NHMs (Figures 1A and S1E ) and identified $600 common to both melanoma cell lines ( Figure 1C ; Table S1 ). GO analysis showed that these genes are involved in cell-cycle and organelle assembly, among others ( Figure S1F) . Integration of the JQ1-sensitive gene signature with genes upregulated in melanoma relative to NHMs ( Figure 1A ) revealed 78 putative pro-tumorigenic genes ( Figure 1D ; Table S1 ). GO classification showed enrichment of gene functions including regulation of DNA metabolic processes, mitosis, and negative regulation of neurogenesis ( Figure S1G ), supporting their roles in melanoma.
Candidate Loss-of-Function Proliferation Screen Reveals AMIGO2 To assess the functional significance of these genes, we selected eight (of the 78 candidates) with little to no evidence of involvement in melanoma pathogenesis, and one positive control gene, HMGA2 (Raskin et al., 2013; Zhang et al., 2015) , to be tested in a loss-of-function mini-screen. We transiently transfected SKmel147 cells with siRNA pools against each of the nine genes and assessed their impact on proliferation (Figure 1E) . Silencing of HMGA2 showed the most significant proliferation defect. Four additional genes, AMIGO2, MED25, ZIC1, and ZBTB38, scored significantly ( Figure 1E ), functionally identifying them as regulators of melanoma cell growth. We validated that these genes are transcriptionally downregulated upon JQ1 treatment in 501MEL and SKmel147 cells by quantitative RT-PCR (qRT-PCR) ( Figure S1H ). Notably, AMIGO2 (1) was significantly downregulated at both time points of JQ1 treatment ( Figures 1D and S1H ), (2) was also sensitive to a clinically relevant BETi, I-BET762 (Mirguet et al., 2013) (Figure 1F ), and (3) represents a BETi-sensitive gene across multiple melanoma cell lines ( Figure 1G ). Based on these findings and the fact that AMIGO2 is a transmembrane molecule, which holds potential as a drug target, we investigated this gene for its role in melanoma biology.
AMIGO2 Is Upregulated in Human Melanoma
We assessed AMIGO2 expression by qRT-PCR in a panel of melanoma cell lines and NHMs and found that AMIGO2 is higher in most melanomas irrespective of genotype ( Figure 2A ). AMIGO2 is also upregulated at the mRNA and protein levels in patient-derived melanoma short-term cultures (STCs) (de Miera et al., 2012) (Figures 2B and 2C) . Furthermore, expression data of two independent cohorts of human patient samples (TCGA Research Network and Xu et al., 2008) show significant upregulation in metastatic versus primary melanoma samples (Figure 2D) and show that AMIGO2 expression is independent of mutational status ( Figure 2E ). We also found significantly increased AMIGO2 protein levels in primary and metastatic melanomas compared to skin melanocytes and nevi by immunohistochemistry using a tissue microarray (Figures 2F-2H ; Table S2 ). LMNB1  DEPDC1  NUF2  KRR1  LINC00152  ZBTB38  MED25  BRIX1  SKP2  KIF23  TPX2  TOP2A  ID3  REOX1  CAP2  MANEAL  HMMR  KIF14  MKI67  TCERG1  CCDC59  NDC80  SMARCAD1  SYTL2  CENPF  TRMT13  ETAA1  THUMPD2  SGOL1  CCDC34  SLC16A7  NOX4  DOCK10  SGOL1-AS  CWC22  AMIGO2  PPAP2C  HMGA2  PTPRF  ZNF37A  WWC1  DLX1  SREK1IP1  SRGAP1  ZNF432  ZDHHC23  LCP1  SYNGAP1  LIMCH1  PDGFC  CNTRL  FAM169A  BAZ2B  MNS1  SHOX2  TBX18  SMAD9  LLRCC1  SEMA3A   EFNA5  ZNF221  ZNF300  HOXA4  SORBS2  PRR5L  RAB39A  E2F8  LOC152225  FAM167A  LOC101926940  ZIC1  IGF2BP1  FST  ANK3  MCIDAS  RAP1GAP2   TCF12   IFI16 824 JQ1 downregulated genes See also Figure S1 and primary data in Table S1 .
All NHMs in skin were negative for AMIGO2; $38% of nevi scored positively, while primary and metastatic melanomas scored 48% and 67%, respectively. In sum, AMIGO2 mRNA and protein levels are significantly higher in human melanoma relative to NHMs, independent of the driver mutation.
AMIGO2 Functions as a Pro-proliferation and Prosurvival Factor In Vitro and In Vivo To assess the effects of AMIGO2 loss of function on melanoma survival, we stably suppressed its expression using four independent shRNAs ( Figure S2A ). AMIGO2 silencing impaired Table S2 .
melanoma cell proliferation and colony formation in 501MEL and SKmel147 cells ( Figures 3A, 3B , S2B, and S2C) and in additional melanoma cell lines irrespective of genetic background (Figure S2D ). To gain a mechanistic understanding of this phenotype, we investigated the effects of AMIGO2 knockdown. Depletion of AMIGO2 resulted in cell-cycle arrest via accumulation of cells in G1 and concomitant decrease in S phase cells ( Figure 3C ). This G1 arrest was followed by apoptosis marked by an increase in Annexin V-positive cells and Caspase-3 activity, which were both blocked by the addition of a pan-Caspase inhibitor, Q-VD-OPh (Ku zelová et al., 2011) , coupled to an increase in PARP cleavage . AMIGO2 knockdown in NHMs did not alter their ability to proliferate ( Figure S2H ). To investigate the consequences of AMIGO2 silencing in vivo, SKmel147 cells stably expressing control (shSCR) or shAMIGO2 were injected into the flanks of immunocompromised mice. Cells expressing shAMIGO2 showed significant reduction in tumor growth and mass versus controls ( Figures 3G and 3H ), further supporting a role for AMIGO2 in proliferation and survival. Together, our data indicate that AMIGO2 is essential for melanoma growth both in vitro and in vivo.
Proteomic and Transcriptomic Analyses in the Context of AMIGO2 Deficiency
To molecularly characterize the role of AMIGO2 in melanoma, we conducted RNA-seq and reverse phase protein array (RPPA) of shAMIGO2-versus shSCR-expressing 501MEL and SKmel147 cells. RPPAs are antibody arrays that include $300 antibodies that detect either total protein or specific post-translational modifications of proteins, many of which are involved in signaling pathways. RNA-seq analysis identified $1,500 deregulated genes upon AMIGO2 depletion in both melanoma cell lines ( Figure S3A ; Table S1 ), five of which were also significantly altered by RPPA (Figures S3A and S3B ; Table S3 ). GO analysis of the RNA-seq revealed enrichment in pathways involved in cell division and proliferation ( Figure S3C ), consistent with the phenotypic effects of AMIGO2 knockdown. Interestingly, RPPA analysis did not show significant and/or consistent changes in components of the MAPK signaling pathway (Figure S3D ), but did reveal significant changes in FOXM1 (Figures  S3B and S3E; Table S3 ), a TF implicated in melanoma proliferation by promoting cell-cycle progression (Bhat et al., 2008; Ito et al., 2016; Miyashita et al., 2015) . Thus, our profiling data suggest that AMIGO2 loss results in transcriptional changes affecting proliferation prior to cell death.
The AMIGO2-PTK7 Axis Mediates Melanoma Survival
To link deficiency of AMIGO2, a transmembrane protein, with downstream transcriptional changes driving cell-cycle arrest and apoptosis, we investigated AMIGO2 protein interactors by affinity purification followed by mass spectrometry. We expressed an AMIGO2-GFP fusion protein, which properly localizes at the membrane in melanoma cells ( Figure 4A ), and found 159 unique interactors (Table S4) . GO analysis showed enrichment in biological processes in which AMIGO2 has been implicated (e.g., cell adhesion, neuron projection) ( Figure 4B ) (Kuja-Panula et al., 2003) . We validated AMIGO2 interaction with five transmembrane proteins (ALCAM, L1CAM, NRP1, NRP2 and PTK7) ( Figures 4C, S4A , and S4B) with reported roles in cancer (Penna et al., 2013; Prud'homme and Glinka, 2012; Valiente et al., 2014) . PTK7 was a consistent interactor across melanoma cell lines ( Figures 4C and S4B ) and co-localizes with AMIGO2 at the cell membrane ( Figure S4C ).
PTK7 is a kinase-dead receptor essential for neural tube formation and altered in cancer Golubkov et al., 2014; Lu et al., 2004) . We investigated whether PTK7 silencing would mimic the pro-apoptotic effects of AMIGO2 loss. PTK7 knockdown with two independent shRNAs (Figures 4D and S4D) significantly impaired cell growth and induced apoptosis in two melanoma cell lines (Figures 4E and 4F) , with concomitant reduction of FOXM1 ( Figures 4D and S4D ). Thus, PTK7 knockdown phenocopies AMIGO2 silencing.
Like other membrane receptors, PTK7 function is regulated by proteolytic processing (Golubkov et al., 2011; Na et al., 2012) . Upon proteolysis by MMP1 or ADAM17, a membrane-bound C-terminal fragment of PTK7 (CTF1) is generated. Further intramembrane proteolysis by g-secretase renders CTF2, which translocates to the nucleus ( Figure S4E ) and has been suggested to modulate gene expression (Na et al., 2012) . We next queried whether AMIGO2 deficiency would alter the processing of PTK7. Indeed, we found that AMIGO2 knockdown results in accumulation of CTF1 and CTF2 ( Figure 4G ). These findings could be replicated by JQ1 treatment ( Figure 4H ). Upon AMIGO2 knockdown, we also found increased levels of nuclear CTF2 ( Figure 4I ). Collectively, our data suggest that AMIGO2 and PTK7 work together to promote melanoma cell survival and that AMIGO2 regulates PTK7 function.
Melanoma SEs Often Associate with Genes Encoding Pro-tumorigenic Factors
Next, we investigated the mechanisms underlying AMIGO2 upregulation in melanoma. Given that oncogene expression and BETi sensitivity are associated with BET occupancy at SEs and promoters (Lové n et al., 2013), we hypothesized that AMIGO2 expression could be driven by BET-occupied enhancers formed during melanocytic transformation. To map melanoma enhancers, we conducted chromatin immunoprecipitation coupled to high-throughput sequencing (ChIP-seq) for BRD4 as a marker of active enhancers (Lové n et al., 2013) and identified 464 SEs and 4,678 typical enhancers (TEs) in SKmel147 cells, also enriched for BRD2 (Figures 5A and 5B; Table S5 ). These enhancers were enriched for H3K27ac and MED1, as previously reported Whyte et al., 2013) (Figure S5A ). We also identified enhancers based on H3K27ac (Lové n et al., 2013; Whyte et al., 2013) , which yielded 1,040 SEs and 12,712 TEs, also enriched for BET proteins (Figures S5B-S5D ; Table S5 ).
We next linked BRD4-identified SEs and TEs to their associated genes and identified 387 and 2,537 genes, respectively, which showed BRD4 and BRD2 enrichment at their promoters (Figures 5B, 5C, and S5E; Table S5 ). We found SE-associated genes to be expressed at higher levels and with higher expression levels over NHMs compared to non-TE-/non-SE-and TEassociated genes, and more sensitive to BETi ( Figure 5D ). Consistent with previous reports (Anders et al., 2014; Vardabasso et al., 2015) , BRD2 is preferentially enriched at promoters compared to enhancers, while BRD4 is enriched at SEs and SEassociated gene promoters ( Figures 5B, 5C , and S5E).
Our BRD4 analysis further revealed that melanoma-associated genes such as LIF, CCND1, and BRD2 (Kuphal et al., 2013; Vardabasso et al., 2015; Vízkeleti et al., 2012) have putative SEs ( Figure 5A ). AMIGO2 was associated with two SEs, and three other genes from the proliferation mini-screen (HMGA2, ZBTB38, and PDGFC) ( Figure 1E ) were also associated with SEs ( Figures 5A, S5B , and S5F). Other genes from the miniscreen, including FST, ZIC1, and TBX18 ( Figure 1E ), were associated with TEs ( Figures 5A, S5B , and S5F).
BETi Displaces BRD4 and BRD2 from SEs and Associated Promoters
To gain mechanistic insight into melanoma BETi sensitivity, we investigated changes in BET occupancy at TEs, SEs, and associated genes upon BETi treatment in SKmel147 cells treated with JQ1 for 6 hr. Upon BET inhibition, we observed depletion of BRD2 and BRD4 from TEs and SEs and, to a lesser extent, from TE/SE-associated promoters ( Figures 5B, 5C , S5E, and S5F), correlating with decreased expression of TE/SE-associated genes ( Figure 5D ). Two BETi-sensitive genes from the mini-screen were not associated with a TE or SE (MED25 and REXO1), suggesting their sensitivity is conferred by BET displacement from their promoters ( Figure S5F ). Collectively, these data suggest that BRD2 and BRD4 occupancy at both promoters and/or enhancers is important for gene activation and that BRD2 and BRD4 eviction from these regulatory elements plays a key role in regulating BETi sensitivity in a locus-specific manner.
Melanoma SEs Are Absent in NHMs and Are Heterogeneous across Cell Lines
To investigate whether the identified SEs were associated with melanocytic transformation, we examined the melanoma SEs in NHMs. While NHMs and melanoma cells displayed comparable levels of BRD2 and BRD4 genome-wide ( Figure S5G ), the majority of melanoma SEs, TEs, and associated gene promoters were depleted of BRD2 and BRD4 in NHM ( Figures 5E, S5F , and S5H). Using Assay for Transposase-Accessible Chromatin (ATAC)-seq and ChIP-seq for H3K4me1 and H3K27ac (Creyghton et al., 2010) , we identified $1,400 constituent enhancers within the SEs of melanoma cells (Table S5) (B) Functional annotation of AMIGO2-interacting proteins detected by GFP pull-down followed by MS in SKmel147 cells stably expressing AMIGO2-GFP (see Table S4 ). Together, this suggests that the transformation of NHMs to melanoma involves the reorganization of the enhancer landscape to promote melanoma gene expression programs.
To investigate enhancer heterogeneity in melanoma, we expanded our analysis to additional cell lines, including 501MEL, SKmel239 (BRAF
V600E
), and SKmel2 (NRAS Q61R ), and an additional NHM line. This analysis showed H3K27ac and H3K4me1 heterogeneity among melanoma cell lines and more so compared to NHMs ( Figure S6A ). Using distance correlation, we classified NHM and melanoma cell lines based on their H3K27ac levels at enhancer regions ( Figure S6A ) and found that NHMs cluster together, yet separately from melanoma ( Figure S6B) . Surprisingly, melanoma lines clustered based on their mutation status for H3K27ac levels within SEs and for expression of their associated genes ( Figure S6B ).
Melanoma SEs Are Regulated by AP1 and TEAD TFs
We next performed motif analysis on the top 150 SEs ( Figure 5B ) and identified JUN and FOSL1/2 (of the AP-1 TF complex), TEAD1/4, and TGIF1/2 ( Figure 5H ), all of which have been implicated in melanoma or other cancers (Agrawal et al., 2017; Ozanne et al., 2007; Verfaillie et al., 2015; Xiang et al., 2015) . ChIP-seq analysis showed FOSL2 and TEAD4 enrichment at melanoma SEs and TEs ( Figures 5I and S6C ). We further found the promoters and TEs/SEs of FOSL1/2 and TEAD1/4 themselves to be BET bound (Figures 5A and S6D ; Table S5 ), yet without changes in their expression levels or BET occupancy upon JQ1 treatment ( Figures S6D, and S6E ; Table S1 ), suggesting these TFs may be insensitive to BETi.
AMIGO2 Is Regulated by BETs and AP1/TEAD TFs
We identified two putative active SEs upstream of the AMIGO2 TSS ($20 kb and $200 kb) in SKmel147 cells ( Figure 6A ). Interestingly, AMIGO2 and its SEs are located within the same putative topologically associating domain (TAD) (Dekker and Heard, 2015) and lamina-associated domain , as suggested by flanking H3K27me3, macroH2A1, and macroH2A2 repressive domains, respectively, as well as CTCF occupancy (Hanssen et al., 2017) ( Figure 6A ). This region also contains PCED1B, which is not expressed (Table S1 ) and therefore unlikely to be regulated by these SEs. We focused on the SE immediately upstream of AMIGO2 due to its presence across multiple melanoma lines (while it is largely absent from NHMs) ( Figure 6B ). Moreover, we found this SE in an additional panel of melanoma cell lines and STCs using published H3K27ac ChIP-seq data (Kaufman et al., 2016; Verfaillie et al., 2015) (Figure 6C ). This suggests that AMIGO2 regulation through this SE is conserved across melanomas independent of mutational status and despite SE heterogeneity ( Figures  S6A and S6B) . Additionally, AMIGO2 expression significantly correlates with H3K27ac levels at this SE ( Figure 6D ).
To further dissect the contribution of BET proteins to AMIGO2 expression and its sensitivity to BETi, we assessed AMIGO2 expression changes upon individual BET knockdown. We observed that BRD2 and BRD4 silencing, but not BRD3 silencing, suppressed AMIGO2 ( Figure 6E) . Moreover, the AMIGO2 locus and its SEs are enriched for BRD2 and BRD4 in melanoma compared to NHM and depleted upon BETi treatment ( Figures 6F and S6F) .
Based on our ATAC-seq and ChIP-seq data in SKmel147 cells, we identified five constituent enhancers (E1-E5) within the AMIGO2 SE ( Figures 6B and 6F ), which were bound by FOSL2 and TEAD4 ( Figure 6G ). Interestingly, E1-E3 were shared between most melanoma lines, and E4 and E5 were predominant in SKmel147 cells ( Figures 6B and 6C ), in accordance with its higher AMIGO2 levels (Figures 2A and 6D ). To determine whether these TFs play a functional role in melanoma and in AMIGO2 regulation, we knocked down FOSL2 and TEAD4/1 in SKmel147 cells (Figures 6H and S6G ). Because the TEAD family members can function in a redundant manner (Verfaillie et al., 2015) , we silenced TEAD4 and TEAD1 simultaneously (Figure S6G ). FOSL2 and TEAD4/1 knockdown significantly abrogated melanoma growth ( Figure S6H ) and suppressed AMIGO2 (Figures 6H and S6G) . Thus, AMIGO2 expression in melanoma and its sensitivity to BETi likely occurs via the action of BETs and the above TFs.
AMIGO2 Expression Is Controlled by Its Upstream SE
To test the functionality of the predicted enhancers ( Figures 6B  and 7A ), we cloned E1-E5 upstream of a minimal promoter driving luciferase expression and transfected these constructs into SKmel147 cells. All enhancers, except E1, promoted transcriptional activity ( Figures 7B and  S7A ). We next used CRISPR/Cas9 editing to individually delete the genomic regions containing E2-E3 and E4-E5 ( Figures 7A,  S7B , and S7C). These deletions suppress AMIGO2 expression relative to a non-edited control ( Figure 7C ). Moreover, using a proliferation competition assay, we observed that deletion of either E2-E3 or E4-E5 confers a growth disadvantage for melanoma cells ( Figure S7D ). Finally, to confirm the contribution of FOSL2 and TEADs to AMIGO2 expression through its SE, we deleted their DNA motifs within E3. We first divided the enhancer into three segments, E3A-C ( Figure 7A, top) , and found E3's activity largely encoded by E3A ( Figure 7D ). Deletion of the FOSL2 and TEAD4/1 motifs within E3A significantly diminished its activity ( Figure 7D ). Collectively, our data confirm that the proximal upstream SE controls AMIGO2 expression in melanoma.
DISCUSSION
Based on the hypothesis that BET proteins orchestrate a transcriptional program that supports melanoma growth, we utilized BET inhibition to identify essential genes in malignant melanoma. We then selected a subset of uncharacterized BETi-sensitive genes that are upregulated in melanoma versus NHM and assessed their contribution to proliferation. We focused on AMIGO2, which encodes a transmembrane protein, and demonstrated a pro-survival role for AMIGO2 in melanoma cells, independent of the driver mutations they harbor.
AMIGO2 is a member of the Amphoterin-induced gene and ORF family and shares similar structure with AMIGO1 and AMIGO3 (Kuja-Panula et al., 2003) . Their extracellular domains contain six LRRs flanked by cysteine-rich domains and an Iglike domain, and the cytosolic regions contain serines and threonines that potentially transduce signaling cues (Rabenau et al., 2004) . AMIGO proteins were discovered in a screen for genes that control adhesion processes necessary for axon extension and fasciculation (Kuja-Panula et al., 2003) . AMIGO2 was independently identified as pro-survival factor of cerebellar granule neurons upon depolarization (Ono et al., 2003) . Recently, AMIGO2 was reported as a pro-survival factor in endothelial cells subjected to hypoxia, thus playing a key role in the vasculature .
Here, we find the kinase-dead receptor PTK7 to interact with AMIGO2 at the membrane. We further showed that AMIGO2 modulation of PTK7 and its cleaved forms regulates melanoma cell survival, independent of the PI3K/AKT and MAPK signaling pathways. Thus, the AMIGO2-PTK7 axis has emerged as a regulator of melanoma survival and an attractive therapeutic target. Interestingly, antibody-drug conjugates against PTK7 have been successfully tested in phase I clinical trials for solid tumors (Damelin et al., 2017) , supporting the development of highaffinity monoclonal antibodies that block the AMIGO2-PTK7 interaction with possible therapeutic efficacy in melanoma.
To comprehend the pro-tumorigenic transcriptional programs of melanoma and the mechanisms by which BET perturbation impacts gene expression programs, we mapped the enhancer landscape of NHMs and melanoma cells. We find that the transformation of NHMs to melanoma involves a significant reorganization of enhancer elements, and that a large number of SE-regulated genes are associated with cancer, as previously proposed . Our data suggest that using BRD4 enrichment to identify SE-regulated genes may be useful for identifying melanoma driver genes. Genome-wide studies of BRD2 revealed that, akin to BRD4, it is enriched at TEs and SEs. However, unlike BRD4, BRD2 preferentially binds promoter regions and CTCF-occupied regions (data not shown) (Hsu et al., 2017) , suggesting distinct yet cooperative roles in transcriptional regulation.
Following BET inhibition, we observed differential genomewide displacement of BRD2 and BRD4 from TEs, SEs, and the promoters of their associated genes, which correlates with reduced expression of JQ1-sensitive genes. Our data suggest, however, that BETi sensitivity is not restricted to genes that are associated with BET-occupied enhancers. BETi sensitivity can also occur through BRD2 and BRD4 eviction from promoters. We also highlight that not all BET-occupied genes are necessarily BETi sensitive, the reasons for which remain unclear, but may involve chromatin architecture or mRNA stability.
As suggested for other cancers (Akhtar-Zaidi et al., 2012; Ooi et al., 2016) , we observed enhancer variation across melanomas. Despite this heterogeneity, we find the AMIGO2 SE to be present in all melanoma cells studied and inactive in NHMs largely through the lack of BET proteins and H3K27ac. We speculate that during transformation, this SE is activated, followed by acquisition of BRD2, BRD4 and FOSL and TEAD TFs (see model, Figures 7E and 7F) . Upon BETi treatment, BET displacement from the AMIGO2 SEs and promoter allows transcriptional downregulation ( Figures 7E and 7F) . However, it remains unclear whether these particular TFs are displaced by BET inhibition and how BET proteins and TFs functionally cooperate at the AMIGO2 SEs.
Our understanding of AMIGO2 function in cancer has been limited (Kanda et al., 2017; Park et al., 2015) , likely due to the lack of evidence for genetic alterations. Here, we report that AMIGO2 is required for melanoma cell proliferation and survival and is induced by the acquisition of active cis DNA regulatory elements absent in NHMs. Ongoing studies will further illuminate AMIGO2 function in cancer and inspire the development of small-molecule inhibitors or antibodies against this transmembrane protein and/or its partner, PTK7.
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EXPERIMENTAL MODELS AND SUBJECT DETAILS
Cell culture 501MEL ( , 2012) . MeWO (Male) were grown in EMEM supplemented with 10% FBS, penicillin and streptomycin. Normal human melanocytes (NHM1-5) were extracted and cultured as follows: Neonatal foreskins were collected in PBS, 1:100 Anti-Anti (100X Antibiotic-Antimycotic (GIBCO, Cat# 15240-062)), and kept at 4 C for no longer than 48 hr. Skins were then washed once in 70% EtOH and 3x in PBS, 1:100 Anti-Anti, cut into 3-4 pieces in HBSS (GIBCO, Cat# 24020-117) and placed in Dispase II solution (Roche, Cat# 04942078001) at 4 C O/N. Epidermis then separated from the dermis in HBSS, floated in 1 mL of 0.25% trypsin (GIBCO, Cat# 15400-054), and incubated in 37 C for 3 min with agitation. Cells were then collected into 4 mL of DMEM with 10% FBS and spun at 1200 rpm for 5 min twice. Media was then removed from the first and the second cell pellets, which were then consolidated and resuspend in Melanocyte Growth Media 254 supplemented with Human Melanocyte Growth Supplement (HMGS, Life Technologies, Cat# S-016-5) and 0.2 mM CaCl 2 , for 3-5 days. Cells were then rinsed in PBS, 1:100 Anti-Anti, and trypsinized in 1 mL 0.05% Trypsin for 3 min to separate melanocytes from fibroblasts and keratinocytes, which take longer to detach. Cells were then collected into 4 mL of DMEM with 10% FBS, and spun at 1200 rpm for 5 min and resuspended and cultured in Melanocyte Growth Media 254 supplemented with HMGS, 0.2 mM CaCl 2 , and 10 ng/mL PMA (Sigma, Cat# P8139).
Mice
NOD/SCID/IL2gR
À/À female mice (Jackson labs, Cat# 05557) were used for in vivo studies. Experiments were conducted following protocols approved by the NYU Institutional Animal Care Use Committee (IACUC) (protocol number, S16-00051).
METHOD DETAILS
IC 50 curves Cells were seeded at 2x10 4 cells per well on a 96-well plate and treated with varying concentrations of JQ1 (JQ1(+)) for 72 hr. Cell viability was measured as described below and results were plotted relative to the lowest concentration.
Reverse transfection
Cells were seeded at 3x10 4 cells per well on a 96-well plate and transfected with Lipofectamine 2000 (Invitrogen) and siRNA ONtarget plus SMARTpools for each of the indicated candidate genes and with siSCR control, at a final concentration of 20 nM (n = 3/siRNA). At 48 hr post-transfection, cells were seeded for cell proliferation screens. 
Cell viability assays
Colony formation assay
Cells were seeded at 1x10 3 cells per well on a 6-well plate (n = 2/condition) and media was changed every 3 days. Fourteen days post-seeding, cells were fixed in 0.1% glutaraldehyde and 0.5% crystal violet. After washing off excess crystal violet, plates were scanned and colony number was manually assessed.
Plasmids, lentiviral vector production and cell transfection To generate AMIGO2-GFP, the human AMIGO2 cDNA was purchased from Dharmacon (pBluescript, MHS6278-202804749) and subcloned into the pLenti-CMV-GFP-Puro vector (Addgene, Cat# 17448) using XbaI (5 0 -GCGGATCCGCagtggacgccacaaaaggtgtgt cagaaaa-3 0 ) and BamHI (5 0 -CTAGTCTAGAATGTCGTTACGTGTACACACTCTGCCCACCCT-3 0 ). For lentiviral vectors production HEK293T cells were seeded in 10 cm tissue culture dish and incubated at 37 C and 5% CO 2 . When cells reached 80% confluency they were co-transfected with 12 mg of lentiviral expression constructs, 8 mg of psPAX2 and 4 mg pMD2.G vectors using Lipofectamine 2000 (Invitrogen) following manufacturer's recommendations. At 48 hr post transfection supernatants were collected, filtered (0.45 mm) and stored at À80 C (Segura et al., 2013) . Melanoma cells were infected with lentiviral supernatant supplemented with polybrene at a final concentration of 4 mg/mL. siRNA ON-target plus SMARTpools were purchased from Dharmacon. 50 nM of the corresponding siRNA were transfected using Lipofectamine 2000 (Invitrogen) following manufacturer's protocol. Transfection efficiency was monitored using 50 nM BLOCK-iT Fluorescent Oligo (Invitrogen).
RNA extraction, Reverse Transcription and qRT-PCR Total RNA was extracted using RNeasy QIAGEN extraction kit according to the manufacturer's protocol. 1 mg of RNA was subjected to DNase I treatment and reverse transcription. Real-time PCR of the gene of interest was performed using SYBR green (Applied Biosystems or Roche). Expression levels are shown relative to PPIA or GAPDH as indicated. For NHM, RNA was further purified using OneStep PCR Inhibitor Removal columns (ZYMORESEARCH, Cat# D6030) to remove melanin prior to qRT-PCR.
Flow cytometry, apoptosis, and cell cycle analysis Cells were seeded at 1.5x10 5 cells per well on 6-well plates (n = 2/condition). For apoptosis measurements, non-adherent and adherent cells were collected and stained with AnnexinV-Pacific Blue (BioLegend, Cat# 640917) and PI, following manufacturer's protocol. For cell cycle analysis, cells were pulsed with EdU (ThermoFisher, Click-IT EdU Pacific Blue Flow Cytometry Assay Kit) for 1 hr, brought to suspension and fixed following manufacturer's protocol. Pulsed cells were co-stained with PI at a final concentration of 10 mg/mL. A BD LSRII cytometer was used for data acquisition and Flowjo software for analysis.
Caspase activity assay Cells were treated with or without a pan-caspase inhibitor (10 nM, QVD) 24 hr post-lentiviral infection. Cells were then rinsed 1x with PBS and resuspended in 1X lysis buffer (20 mM HEPES/NaOH, pH 7.2, 10% sucrose, 150 mM NaCl, 10 mM DTT, 5 mM EDTA, 1% Igepal CA-630, 0.1% CHAPS, and 1X EDTA-free Complete protease inhibitor mixture (Roche)). Lysates were cleared by centrifugation at 16,000xg for 5 min and supernatants quantified by the Lowry method (Bio-Rad). Assays were performed in triplicate using 25 mg of protein in lysis buffer supplemented with 25 mM of the fluorogenic substrate Ac-DEVD-afc. Plates were read in a fluorimeter using a 400 nm excitation filter and a 505 nm emission filter.
Whole cell protein extractions and western blot analysis Cells were harvested with PathScan Sandwich ELISA 1X lysis buffer (Cell Signaling Cat# 7018) supplemented with protease and phosphatase inhibitor cocktail (Roche). Cell lysates (15-40 mg of protein) were resolved in 4%-12% Bis-Tris gels (Invitrogen) and transferred to nitrocellulose membranes using semi-dry transfer. After blocking (1 hr to overnight with 5% nonfat milk), membranes were probed with primary antibodies overnight at 4 C. Membranes were developed using Clarity western ECL blotting substance (Biorad, Cat# 1705060). For AMIGO2, primary antibody was used at 1:100 (R&D systems). Secondary detection was performed using rabbit anti-goat at 1:20,000 (Sigma, Cat# A5420). Immunoblots were done on whole-cell lysates unless otherwise indicated.
Immunohistochemistry (IHC)
Unconjugated anti-human AMIGO2, raised against full-length human AMIGO2 was used for IHC. Antibody optimization was performed on formalin-fixed, paraffin-embedded 4-micron composite tissue microarrays containing normal and tumor: skin, stomach, prostate, liver, and pancreas. IHC parameters were validated on formalin-fixed, paraffin-embedded 4-micron human hippocampus with cells clearly expressing cytoplasmic-membrane staining considered positive. Chromogenic IHC was performed on a Ventana Medical Systems Discovery XT instrument with online deparaffinization using Ventana's reagents and detection kits unless otherwise noted (Ventana Medical Systems Tucson, AZ USA). AMIGO2 was antigen-retrieved in Ventana Cell Conditioner 1 (Tris-Borate-EDTA) for 20 min. Antibody was diluted 1:50 in PBS and incubated for 6 hr at room temperature. Primary antibody was detected with goat anti-mouse, horseradish peroxidase conjugated multimer incubated for 8 min. The complex was visualized with alpha-naphthol pyronin incubated for 8 min. Slides were washed in distilled water, counterstained with Hematoxylin, dehydrated and mounted with permanent media. Negative controls were incubated with diluent instead of primary antibody. Staining score was performed in a blinded manner. The IHC score was calculated using staining intensity (1-4) x percentage of positive cells.
Immunofluorescence SKmel147 cells were grown on glass coverslips (SKmel147 cells stably expressing AMIGO2-GFP were used in Figure 4A ), fixed in 4% PFA for 15 min and permeabilized with 100 mM saponin for 30 min. Primary antibodies were used at the following dilutions: AMIGO2 1:500 ( Figure 4A ), and AMIGO2 1:200 and PTK7 1:200 ( Figure S4C ). Secondary detection was performed using Alexa Fluor conjugated antibodies diluted 1:1000, nuclei were counterstained with Hoechst 33342 and coverslips were mounted in ProLong Diamond Antifade (ThermoFisher). Images were acquired on a LSM 780 confocal microscope controlled by ZEN software (Carl Zeiss) using a 40x immersion objective, 2x internal magnification and optimal voxel size. Single Z slices are shown.
Affinity purification and mass spectrometry (MS) analysis SKmel147 cells stably expressing AMIGO2-GFP or GFP were fixed with 1% formaldehyde for 10 min at RT. Fixing reaction was quenched with 2.5 mM glycine. Whole cell extracts were harvested with 1X lysis buffer (10 mM Tris pH 7.5, 150 mM NaCl, 0.5 mM EDTA, 0.5% NP-40) supplemented with phospatase and protease inhibitors (Roche). 1 mg of protein was incubated with 25 mL of washed beads O/N, washed 3x with wash buffer (1 mM Tris pH 7.5, 150 mM NaCl, 0.1% NP-40, supplemented with phosphatase and protease inhibitors), and eluted in 2X sample buffer. Samples were then run on NuPAGE 4%-12% Bis-Tris Gel 1.0 mm (Life Technologies) and desired fractions were extracted and subsequently digested with trypsin. Peptides were extracted using Poros beads (Life Technologies) for MS analysis. LC separation was conducted with the auto sampler of an EASY-nLC 1000 (ThermoFisher). Peptides were gradient eluted from the column directly to QExactive mass spectrometer using a 90 min gradient (ThermoFisher). For identification of AMIGO2 unique interactors, we determined the peptides uniquely found in AMIGO2-GFP pull downs versus GFP (n = 3). We then filtered out potential contaminants using a contaminant repository (CRAPome (Mellacheruvu et al., 2013) ) with a threshold of > 3/411 (Table S5) .
Mouse experiments
SKmel147 cells were infected with shSCR or shAMIGO2 lentivirus (shA2 #2) for 2 days and then injected at 5X10 5 cells per mouse in the flanks of female NOD/SCID/IL2gR À/À mice (n = 8/group). Tumor volume was measured every 2-3 days over a period of 18 days and tumor weight was measured at endpoints.
TF motif analysis
Enriched TFs DNA binding motifs (De Novo) were identified with a 1000bp window centered on 569 BRD4 significant peaks within the SKmel147 top 150 BRD4 SEs ( Figure 5A , 5B), using HOMER suite (findMotifsGenome.pl; version 4.8) (Heinz et al., 2010) . Motifs were considered based on p value (p < 10 À12 ) and expression levels in SKmel147.
Dendrograms
Normalized total ChIP-seq H3K27ac reads within 464 SKmel147 SEs for NHM1, NHM2, 501MEL and SKmel239 (BRAF
V600E
), and SKmel2 and SKmel147 (NRAS Q61R ) melanoma cell lines were calculated using the ROSE algorithm. Correlations were calculated based on distance correlation (R; energy package). Distances were defined as 1-abs(corr) and were calculated in R, and dendrograms were drawn using a neighbor-joining algorithm (R; ape package). Normalized expression levels of 387 SE associated genes in SKmel147 across all cell lines, were used to generate the expression Dendrogram ( Figure S6A ).
Mosaic plots
Mosaic plots were generated using GEDI (Gene Expression Dynamics Inspector) (Eichler et al., 2003) on H3K27ac ChIP-seq signal within 5142 BRD4 identified SKmel147 TEs and SEs. H3K27ac signal across four melanoma and 2 NHM samples was calculated using ROSE. Maps of size 50x50.
GO analysis GO terms were obtained using Enrichr (Kuleshov et al., 2016) . Combined score of top categories is shown for all plots.
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical methodologies
Statistical analysis was performed using unpaired Student's t test unless otherwise indicated (for Figures 1B and 1C , paired Student's t test was used). Statistical tests performed as part of the RNA-seq, ChIP-seq, and ATAC-seq analyses are detailed in relevant sections above. Error bars for boxplots represent 10-90 percentile with outliers omitted, unless otherwise indicated. For growth curves ( Figure S6H ), nonlinear regression (curve fit) was used to determine significance. For competition assay ( Figure S7D ), Welch's t test was used. P values are represented as *p < 0.05, **p < 0.01 and ***p < 0.001.
DATA AND SOFTWARE AVAILABILITY
Data deposition
The raw and processed sequencing data have been deposited to GEO under accession number: GSE94488. Raw data for immunoblots and for AMIGO2 Mass Spectrometry have been deposited to Mendeley Data and are available at https://doi.org/10.17632/ 8g4vcy4ymm.1.
